| 000 | 01807 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516092616.0 | ||
| 264 | 0 | _c20130430 | |
| 008 | 201304s 0 0 eng d | ||
| 022 | _a1468-2060 | ||
| 024 | 7 |
_a10.1136/annrheumdis-2011-201228 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRaterman, Hennie G | |
| 245 | 0 | 0 |
_aHDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. _h[electronic resource] |
| 260 |
_bAnnals of the rheumatic diseases _cApr 2013 |
||
| 300 |
_a560-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xtherapeutic use |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aApolipoproteins A _xanalysis |
| 650 | 0 | 4 |
_aApolipoproteins B _xanalysis |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xblood |
| 650 | 0 | 4 |
_aAtherosclerosis _xblood |
| 650 | 0 | 4 |
_aCholesterol, HDL _xanalysis |
| 650 | 0 | 4 |
_aCholesterol, LDL _xanalysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunomodulation _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProteomics |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTriglycerides _xanalysis |
| 700 | 1 | _aLevels, Han | |
| 700 | 1 | _aVoskuyl, Alexandre E | |
| 700 | 1 | _aLems, Willem F | |
| 700 | 1 | _aDijkmans, Ben A | |
| 700 | 1 | _aNurmohamed, Michael T | |
| 773 | 0 |
_tAnnals of the rheumatic diseases _gvol. 72 _gno. 4 _gp. 560-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/annrheumdis-2011-201228 _zAvailable from publisher's website |
| 999 |
_c21784486 _d21784486 |
||